Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 4/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309130 | 0.86 | FOLH1 (0.47) | KMT2AATMMEN1FOLH1PLG | |
| SCHEMBL25963767 | 0.83 | FOLH1 (0.45) | KMT2AATMMEN1FOLH1PLG | |
| SCHEMBL30309090 | 0.78 | PLG (0.49) | KMT2AATMMEN1FOLH1PLG | |
| SCHEMBL30309109 | 0.76 | FOLH1 (0.43) | KMT2AATMMEN1FOLH1PLG | |
| SCHEMBL25963760 | 0.76 | PLG (0.47) | KMT2AATMMEN1FOLH1PLG | |
| SCHEMBL25964575 | 0.75 | KMT2A (0.68) | KMT2AATMMEN1 | |
| SCHEMBL30309096 | 0.75 | KMT2A (0.68) | KMT2AATMMEN1 | |
| SCHEMBL30309110 | 0.72 | FOLH1 (0.42) | FOLH1 | |
| SCHEMBL29678851 | 0.71 | PLG (0.54) | PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL29678999 | 0.71 | FOLH1 (0.44) | KMT2AATMMEN1FOLH1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | KMT2A 2730/4885ATM 114/4885MEN1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.